A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers

Medicine (United States)

Volumn 96, Issue 9, 2017, Pages

  Liu, Man ^a   Xing, Lu Qi ^a   Liu, Yi Jing ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

diagnosis; lncRNAs; receiver operating characteristic analysis; triple negative breast cancer

Indexed keywords

LONG UNTRANSLATED RNA; TUMOR MARKER; ANRIL LONG NON-CODING RNA, HUMAN; LONG NONCODING RNA HIF1A-AS2, HUMAN; UCA1 RNA, HUMAN;

ADULT; AGED; ANRIL GENE; ARTICLE; BLOOD LEVEL; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; GENE LOCUS; HIF1A AS2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; UCA1 GENE; UPREGULATION; BLOOD; CARCINOMA, DUCTAL, BREAST; FEASIBILITY STUDY; MIDDLE AGED; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, DUCTAL, BREAST; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; RNA, LONG NONCODING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85015825752     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006222     Document Type: Article

References (42)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
3. Yin WJ, Lu JS, Di GH, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009;115:325-33.
4. Basso SM, Santeufemia DA, Fadda GM, et al. Advances in the treatment of triple-negative early breast cancer. Med Chem 2016;12:268-72.
5. Redis RS, Sieuwerts AM, Look MP, et al. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget 2013;4:1748-62.
6. Chen YA, Aravin AA. Non-coding RNAs in transcriptional regulation: the review for current molecular biology reports. Curr Mol Biol Rep 2015;1:10-8.
7. Latos PA, Pauler FM, Koerner MV, et al. Airn transcriptional overlap, but not its lncRNA products, induces imprinted Igf2r silencing. Science 2012;338:1469-72.
8. Han L, Ma P, Liu SM, et al. Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects. Tumour Biol V 37 2016;6847-54.
9. Malih S, Saidijam M, Malih N. A brief review on long noncoding RNAs: a new paradigm in breast cancer pathogenesis, diagnosis and therapy. Tumour Biol V 37 2016;1479-85.
10. Rao D, Kimler BF, Nothnick WB, et al. Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers. Hum Pathol 2015;46:876-83.
11. Lv M, Xu P, Wu Y, et al. LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer. Oncotarget 2016;7:13047-59.
12. Takeda R, Naka A, Ogane N, et al. Impact of expression levels of platinum-uptake transporters copper transporter 1 and organic cation transporter 2 on resistance to anthracycline/taxane-based chemotherapy in triple-negative breast cancer. Breast Cancer (Auckl) 2015;9:49-57.
13. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J National Cancer Instit 2011;103:1656-64.
14. Synnestvedt M, Borgen E, Russnes HG, et al. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. Acta Oncol (Stockholm, Sweden) 2013;52:91-101.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002;41:154-61.
16. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 2014;15:7-21.
17. Deng R, Liu B, Wang Y, et al. High expression of the newly found long noncoding RNA Z38 promotes cell proliferation and oncogenic activity in breast cancer. J Cancer 2016;7:576-86.
18. Meng J, Li P, Zhang Q, et al. A four-long non-coding RNA signature in predicting breast cancer survival. J Exp Clin Cancer Res 2014;33:84.
19. Chen H, Xu J, Hong J, et al. Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance. Mol Oncol 2014;8:1393-403.
20. Zhou M, Zhong L, Xu W, et al. Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients. Sci Rep 2016;6:31038.
21. Chen C, Li Z, Yang Y, et al. Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer. Cancer Biol Ther 2015;16:856-65.
22. Qi P, Zhou XY, Du X. Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol Cancer 2016;15:39.
23. Isin M, Ozgur E, Cetin G, et al. Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta 2014;431:255-9.
24. Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010; 42:504-7.
25. Lin L, Gu ZT, Chen WH, et al. Increased expression of the long non-coding RNA ANRIL promotes lung cancer cell metastasis and correlates with poor prognosis. Diagn Pathol 2015;10:14.
26. Hua L, Wang CY, Yao KH, et al. High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol 2015;8:3076-82.
27. Qiu JJ, Lin YY, Ding JX, et al. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. Int J Oncol 2015;46:2497-505.
28. Zhang EB, Kong R, Yin DD, et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 2014;5: 2276-92.
29. Zhao JJ, Hao S, Wang LL, et al. Long non-coding RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells through TGF-beta/Smad signaling pathway. Oncotarget 2016;7: 57903-18.
30. Royds JA, Pilbrow AP, Ahn A, et al. The rs11515 polymorphism is more frequent and associated with aggressive breast tumors with increased ANRIL and decreased p16 (INK4a) expression. Front Oncol 2015;5:306.
31. Meseure D, Vacher S, Alsibai KD, et al. Expression of ANRIL-polycomb complexes-CDKN2A/B/ARF genes in breast tumors: identification of a two-gene (EZH2/CBX7) signature with independent prognostic value. Mol Cancer Res 2016;14:623-33.
32. Rossignol F, Vache C, Clottes E. Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues. Gene 2002;299:135-40.
33. Chen WM, Huang MD, Kong R, et al. Antisense long noncoding RNA HIF1A-AS2 is upregulated in gastric cancer and associated with poor prognosis. Dig Dis Sci 2015;60:1655-62.
34. Mineo M, Ricklefs F, Rooj AK, et al. The long non-coding RNA HIF1A-AS2 facilitates the maintenance of mesenchymal glioblastoma stem-like cells in hypoxic niches. Cell Rep 2016;15:2500-9.
35. Chen M, Zhuang C, Liu Y, et al. Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Lett 2016;376: 155-64.
36. Wang XS, Zhang Z, Wang HC, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res 2006;12:4851-8.
37. Zheng Q, Wu F, Dai WY, et al. Aberrant expression of UCA1 in gastric cancer and its clinical significance. Clin Transl Oncol 2015;17: 640-6.
38. Huang J, Zhou N, Watabe K, et al. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis 2014;5:e1008.
39. Chen S, Shao C, Xu M, et al. Macrophage infiltration promotes invasiveness of breast cancer cells via activating long non-coding RNA UCA1. Int J Clin Exp Pathol 2015;8:9052-61.
40. Xiao C, Wu CH, Hu HZ. LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci 2016;20:2819-24.
41. Li X, Wu Y, Liu A, et al. Long non-coding RNA UCA1 enhances tamoxifen resistance in breastcancer cells through a miR-18a-HIF1alpha feedback regulatory loop. Tumour Biol 2016;37:14733-43.
42. Lee JJ, Kim M, Kim HP. Epigenetic regulation of long noncoding RNA UCA1 by SATB1 in breast cancer. BMB Rep 2016;49:578-83.